Loading
NASDAQHealthcareMedical - Diagnostics & Research
Latest quote
$218.22
−$3.44 · -1.55%
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Previous close
$218.22
−$3.44 · -1.55%
Regular session · ET · Market data may be delayed.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Day range
Current $218.22
52-week range
Current $218.22
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Buy
Favorable setup — positive multi-factor alignment
Valuation
84
Deep Value
Sentiment
54
Mixed
Risk
38
Moderate Risk
Momentum
72
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Day range
Current $218.22
52-week range
Current $218.22
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4.34B USD | 4.37B USD | 4.5B USD | 4.58B USD | 4.53B USD |
| Cost of goods sold | 1.45B USD | 1.51B USD | 1.76B USD | 1.61B USD | 1.37B USD |
| Gross profit | 2.89B USD | 2.86B USD | 2.74B USD | 2.97B USD | 3.15B USD |
| Research and development | 951M USD | 1.17B USD | 1.35B USD | 1.32B USD | 1.19B USD |
| Selling, general, and administrative | 1.08B USD | 1.09B USD | 1.61B USD | 1.3B USD | 2.09B USD |
| Operating expenses | 2.03B USD | 3.69B USD | 3.81B USD | 7.15B USD | 3.28B USD |
| Interest income | 40M USD | 46M USD | 58M USD | 11M USD | — |
| Interest expense | 101M USD | 100M USD | 77M USD | 26M USD | 61M USD |
| Depreciation and amortization | 270M USD | 354M USD | 432M USD | 394M USD | 251M USD |
| Operating income | 864M USD | −833M USD | −1.07B USD | −4.18B USD | −123M USD |
| Net income | 850M USD | −1.22B USD | −1.16B USD | −4.4B USD | 762M USD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$204.5
6.29% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 23, 2008 | 2:1 | — | — |
Effective Sep 23, 2008
2:1
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Mid-Cap ETFIJH1.01B0.79%124.57B USD0.05%$75.85+0.13%
Vanguard Morningstar Total Stock Market ETFVTI938.81M0.04%2.3T USD0.03%$379.73-0.32%
Vanguard Morningstar Small-Cap ETFVB677.59M0.37%183.4B USD0.03%$300.01+0.05%
Vanguard Extended Market ETFVXF357.43M0.37%93.7B USD0.05%$242.66+0.14%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY246.28M0.93%26.51B USD0.23%$691.52+0.13%
Invesco S&P MidCap Quality ETFXMHQ244.47M4.36%5.61B USD0.30%$118.08-0.25%
iShares Biotechnology ETFIBB232.41M2.20%10.72B USD0.44%$211.92-0.88%
Vanguard Morningstar Small-Cap Value ETFVBR215.22M0.31%68.3B USD0.05%$247.11+0.08%iShares Core S&P Mid-Cap ETFIJHVanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFState Street SPDR S&P MIDCAP 400 ETF TrustMDYInvesco S&P MidCap Quality ETFXMHQiShares Biotechnology ETFIBBVanguard Morningstar Small-Cap Value ETFVBRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
